| Indication | Clinical Dehydration, Deficiencies, Malabsorption, Off-label Wellness |
| Access | Rx / Clinician Administered |
| Dosing Sched | Acute clinical indication; Elective weekly/monthly |
| Safety Profile | Moderate (Vascular & Compound Risks) |
| Key Marker | G6PD, Electrolytes, Renal Function, Infiltration Scale |
| Est. Cost | $150 - $600 per infusion |
Intravenous (IV) infusions deliver fluids, electrolytes, vitamins, and minerals directly into the systemic circulation, bypassing gastrointestinal absorption. While clinically essential for severe dehydration, acute deficiencies, or malabsorption syndromes, elective wellness infusions in healthy populations require careful assessment of potential vascular risks and compounding sterility against limited clinical outcome data.
Key points (high-level summary)
What people use it for
Intravenous (IV) infusion refers to the controlled administration of fluids, electrolytes, nutrients, or pharmacological agents directly into a vein. By bypassing the enterocytes of the small intestine, IV delivery avoids the rate-limiting steps of active transport, passive diffusion, and first-pass hepatic metabolism. This achieves 100% bioavailability of the infusate and produces immediate peak plasma concentrations that cannot be matched by oral administration.
In standard clinical medicine, IV therapy is reserved for acute scenarios: fluid resuscitation in hypovolemic shock, replacement in severe dehydration, parenteral nutrition in gastrointestinal failure, and delivery of medications with narrow therapeutic windows. In contrast, wellness and longevity medicine has popularized elective outpatient infusions. These formulations range from simple balanced crystalloids for hydration to complex mixtures of water-soluble vitamins, minerals, antioxidants, and biochemical cofactors.
| Outcome / Goal | Effect* | Consistency** | Evidence quality | Trials*** | Notes (population, duration, dose) |
|---|---|---|---|---|---|
| Intravascular Hydration | High | High | >10 RCTs | Buffered crystalloids preferred over 0.9% saline to prevent AKI and hyperchloremic acidosis [1]. Excessive volume in normovolemic patients leads to rapid extravascular drift [2]. | |
| Fibromyalgia & Pain (Myers' Cocktail) | Low | Moderate | 1 RCT | Weak pilot data showed improvement from baseline, but no statistically significant difference over placebo saline infusion [3]. | |
| Cellular NAD+ Repletion | High | Moderate | 1 PK trial | 750 mg IV over 6 hours elevates plasma NAD+ and saturates salvage pathways; requires slow infusion rates due to rate-dependent side effects [4][5]. | |
| Skin Lightening (Glutathione) | Low | Very Low | Insufficient data | Extremely short plasma half-life (<10 min) and rapid cellular breakdown; clinical trials show no robust efficacy and highlight high safety concerns [6]. | |
| High-Dose Ascorbate (Oncology Adjuvant) | Moderate | Moderate | Multiple trials | Investigational oncology use only; achieves millimolar plasma concentrations that act as pro-oxidants to generate hydrogen peroxide [7]. Not indicated for general longevity. |
<effect e="[dir][mag][impact]"></effect> where dir = u|d|e|q, mag = 0|1|2|3, impact = p|n|x. Examples: ↓↓ (p) -> <effect e="d2p"></effect>, = (x) -> <effect e="e0x"></effect>, ? -> <effect e="q0x"></effect>.The concept of intravenous (IV) therapy dates back to the 15th century with early, albeit unsuccessful, attempts at blood transfusions. Significant advancements occurred in the 17th century with experiments on animals, and later in the 19th century, with the pioneering work of Thomas Latta using IV fluid replacements for cholera treatment in 1831, and James Blundell's use of intravenous blood for postpartum hemorrhage. However, IV therapy did not become widely available until the 1950s after further developments in the 1930s. The practice of providing complete nutritional needs intravenously, known as total parenteral nutrition (TPN), began to be explored in the 1960s with the introduction of protein hydrolysates and dextrose, followed by fat emulsions and vitamins in 1975.
When a crystalloid solution is infused, its distribution is dictated by volume kinetics and osmotic gradients [2:1]. In a normovolemic individual, only about 20% to 25% of the infused volume remains within the intravascular space after one hour, with the rest drifting into the interstitial space. If administered too rapidly, the sudden increase in hydrostatic pressure can damage the endothelial glycocalyx, leading to accelerated extravascular drift, tissue edema, and increased cardiac pre-load without improving tissue oxygenation [2:2]. Additionally, the choice of crystalloid affects acid-base chemistry. Large-volume administration of 0.9% normal saline provides supra-physiological chloride concentrations (154 mEq/L), which can induce hyperchloremic metabolic acidosis and trigger renal vasoconstriction, increasing the risk of acute kidney injury compared to buffered crystalloid solutions [1:1].
Intravenous NAD+ administration bypasses cellular barriers to rapidly enter systemic circulation. Pharmacokinetic modeling demonstrates that during a slow 750 mg infusion, plasma NAD+ levels do not rise significantly during the first two hours, suggesting immediate tissue uptake and rapid utilization by intracellular enzymes [4:1]. By the late stages of a six-hour infusion, systemic salvage pathways—which convert NAD+ and its breakdown products (such as nicotinamide and adenosine)—become fully saturated. This results in a massive accumulation of both unmetabolized NAD+ and its primary metabolites in the plasma and urine [4:2].
Extracellular glutathione (GSH) is highly unstable in plasma and has a half-life of less than 10 minutes [6:1]. Upon entering the circulation, IV glutathione is rapidly degraded by the cell-surface enzyme gamma-glutamyltransferase (GGT) into its constituent amino acids: glutamate, cysteine, and glycine. Consequently, the physiological benefit of IV glutathione is primarily mediated by delivering these precursor amino acids to cells for de novo intracellular GSH synthesis, rather than the direct uptake of intact glutathione molecules [6:2][8].
At low oral doses, vitamin C (ascorbate) acts as a potent antioxidant. However, when administered intravenously, it bypasses intestinal absorption limits to achieve millimolar plasma concentrations [7:1]. At these high levels, ascorbate behaves as a pro-drug, undergoing oxidation in the extracellular fluid to produce dehydroascorbic acid and generating high concentrations of hydrogen peroxide () [7:2]. This localized oxidative stress selectively damages cells with impaired antioxidant systems (such as tumor cells), which forms the scientific basis for its investigational use in clinical oncology [7:3].
Clinical rehydration must be tailored to the patient’s volume status and underlying health. In cases of severe dehydration, structured protocols utilizing balanced crystalloids (e.g., Lactated Ringer's, Plasma-Lyte) are preferred over normal saline to maintain electrolyte stability and protect renal function [9][1:2].
To prevent severe rate-dependent adverse effects, IV NAD+ must be administered via slow micro-infusion over 3 to 6 hours [4:3][5:1]. Rates typically start at 100 mg/hour and are adjusted based on patient tolerance. Alternatively, intravenous nicotinamide riboside (NR) has demonstrated superior tolerability profiles, requiring shorter infusion times with fewer transient systemic symptoms [5:2].
High-dose vitamin C infusions (typically exceeding 15 grams) require strict clinical pre-screening. Clinicians must verify normal kidney function and screen for glucose-6-phosphate dehydrogenase (G6PD) deficiency to prevent life-threatening complications [10][11].
Invasive vascular access carries inherent procedural risks. The most common local complications include:
Consistent monitoring using standardized infiltration scales is essential to identify and manage complications before they cause permanent tissue damage [12:1].
The osmolarity of an IV solution dictates its compatibility with peripheral veins. Solutions exceeding 900 mOsm/L are highly hypertonic and carry a high risk of chemical phlebitis, endothelial damage, and vascular injury [14]. Elective wellness infusions containing high concentrations of micronutrients or minerals must be properly diluted in adequate volumes of sterile water or saline to keep the final osmolarity within a safe range for peripheral administration [14:1].
Glucose-6-phosphate dehydrogenase (G6PD) is a critical enzyme required to maintain red blood cell membrane integrity under oxidative stress. When a patient with G6PD deficiency receives high-dose IV vitamin C, the massive generation of extracellular hydrogen peroxide causes severe lipid peroxidation of the red blood cell membrane, leading to life-threatening intravascular hemolysis [10:1]. G6PD screening is an absolute clinical prerequisite before initiating any high-dose ascorbate therapy [10:2].
Ascorbate is metabolically cleared by conversion to oxalate, which is excreted by the kidneys. Ingesting massive doses of IV vitamin C can lead to a rapid spike in urinary oxalate levels. In susceptible individuals, particularly those with pre-existing renal impairment or dehydration, this can trigger the precipitation of calcium oxalate crystals in the renal tubules, resulting in acute kidney injury (AKI) [11:1].
Compounded sterile preparations (CSPs) are highly vulnerable to microbial contamination if prepared under sub-standard conditions. To ensure safety, all sterile IV solutions must be prepared in strict compliance with USP Chapter <797> standards [15]. This requires specialized cleanrooms, ISO-classified laminar flow hoods, strict gowning and sanitization protocols, and regular sterile testing [15:1][16]. Non-compliance with these compounding standards is a primary cause of severe clinical contamination, which can lead to life-threatening sepsis or fungal meningitis [15:2].
The duration depends on the volume and specific ingredients of the infusate. Standard hydration and vitamin bags (500–1000 mL) typically take 45 to 90 minutes. However, specialized infusions like NAD+ must be administered very slowly over 3 to 6 hours to avoid severe rate-dependent discomfort [4:4][5:3].
For healthy individuals with intact gastrointestinal tracts, oral hydration is safer, cheaper, and highly effective. IV hydration is medically indicated when oral intake is impossible (due to severe vomiting, shock, or swallowing difficulties) or when rapid volume expansion is clinically necessary [9:1][2:3].
Infusing NAD+ too quickly can trigger transient, uncomfortable symptoms including intense chest pressure, abdominal cramping, nausea, headache, flushing, and muscle soreness. These symptoms resolve immediately when the infusion rate is slowed or temporarily paused [5:4].
High-dose IV vitamin C acts as a pro-oxidant, generating hydrogen peroxide in the blood. Red blood cells in individuals with G6PD deficiency cannot tolerate this oxidative stress, which can trigger severe, life-threatening intravascular hemolysis [10:3].
The primary risks relate to sterile compounding and clinical oversight. Many elective hydration clinics may lack the strict cleanroom facilities required by USP <797>, increasing the risk of bacterial contamination and subsequent sepsis [15:3][16:1]. Additionally, inadequate pre-infusion screening can lead to serious complications in patients with undiagnosed kidney or heart conditions.
Delgado Moya FP, et al. Buffered solutions versus 0.9% saline for resuscitation in critically ill adults and children. Cochrane Database of Systematic Reviews. 2026. https://pubmed.ncbi.nlm.nih.gov/42011817/ ↩︎ ↩︎ ↩︎
OBrien J, et al. Revisiting the fluid challenge and stroke volume optimisation after induction of general anaesthesia. Annals of Intensive Care. 2026. https://pubmed.ncbi.nlm.nih.gov/42282954/ ↩︎ ↩︎ ↩︎ ↩︎
Ali A, et al. Intravenous micronutrient therapy (Myers' Cocktail) for fibromyalgia: a placebo-controlled pilot study. Journal of Alternative and Complementary Medicine. 2009. https://pubmed.ncbi.nlm.nih.gov/19250003/ ↩︎
Grant R, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Frontiers in Aging Neuroscience. 2019. https://pubmed.ncbi.nlm.nih.gov/31572171/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Reyna J, et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD(+)) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Frontiers in Aging. 2026. https://pubmed.ncbi.nlm.nih.gov/41704678/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Davids LM, et al. Intravenous glutathione for skin lightening: Inadequate safety data. South African Medical Journal. 2016. https://pubmed.ncbi.nlm.nih.gov/27499402/ ↩︎ ↩︎ ↩︎
Böttger F, et al. High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer. Journal of Experimental & Clinical Cancer Research. 2021. https://pubmed.ncbi.nlm.nih.gov/34717701/ ↩︎ ↩︎ ↩︎ ↩︎
AlGhamdi A, et al. Safety and efficacy of parenteral glutathione as a promising skin lightening agent: A controlled assessor blinded pharmacohistologic and ultrastructural study in an animal model. Dermatologic Therapy. 2020. https://pubmed.ncbi.nlm.nih.gov/31885127/ ↩︎
Dewez JE, et al. Intravenous rehydration in children with severe malnutrition and severe dehydration: a systematic review and meta-analysis. Archives of Disease in Childhood. 2026. https://pubmed.ncbi.nlm.nih.gov/42161576/ ↩︎ ↩︎
Quinn J, et al. Effect of High-Dose Vitamin C Infusion in a Glucose-6-Phosphate Dehydrogenase-Deficient Patient. Case Reports in Medicine. 2017. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727655/ ↩︎ ↩︎ ↩︎ ↩︎
Wong K, et al. Acute oxalate nephropathy after a massive intravenous dose of vitamin C. Australian and New Zealand Journal of Medicine. 1994. https://pubmed.ncbi.nlm.nih.gov/7980244/ ↩︎ ↩︎
Liu X, et al. Intraoperative peripheral intravenous complications in adults: a summary of evidence for prevention and management of infiltration/extravasation. Frontiers in Medicine. 2026. https://pubmed.ncbi.nlm.nih.gov/42180784/ ↩︎ ↩︎
Charles KR, et al. Clinically indicated removal versus routine removal of peripheral venous catheters. Cochrane Database of Systematic Reviews. 2026. https://pubmed.ncbi.nlm.nih.gov/41589916/ ↩︎
Huang L, et al. Safety of peripheral intravenous administration of hypertonic saline: a systematic review and meta-analysis. Frontiers in Medicine. 2025. https://pubmed.ncbi.nlm.nih.gov/41306508/ ↩︎ ↩︎
Kastango ES. Compounding USP <797>: inspection, regulation, and oversight of sterile compounding pharmacies. JPEN. Journal of Parenteral and Enteral Nutrition. 2012. https://pubmed.ncbi.nlm.nih.gov/22275322/ ↩︎ ↩︎ ↩︎ ↩︎
Peters M, et al. Achievement of USP Chapter 797 Compliance By A 35-Bed Rural Hospital: A Case Study. International Journal of Pharmaceutical Compounding. 2007. https://pubmed.ncbi.nlm.nih.gov/23994807/ ↩︎ ↩︎